Compensation to clinical trial participants in India: A gap analysis
Author(s) -
Mohd Urooj,
Gulam Mohammed Husain,
MohammadAhmed Khan,
MunawwarHusain Kazmi
Publication year - 2017
Publication title -
international journal of pharmaceutical investigation
Language(s) - English
Resource type - Journals
eISSN - 2230-973X
pISSN - 2230-9713
DOI - 10.4103/jphi.jphi_31_17
Subject(s) - clarity , compensation (psychology) , clinical trial , government (linguistics) , business , risk analysis (engineering) , medicine , intensive care medicine , public relations , psychology , political science , pathology , social psychology , biochemistry , chemistry , linguistics , philosophy
The recent amendments notified by the Government of India, for conducting clinical trial, is greatly appreciable as promoting safety and well-being of human subjects. These rules clearly state that medical management of injuries in clinical trials is mandatory, and clinical trial-related injury or death needs to be compensated over and above the medical management. These rules need to be reconsidered for simplification and better understanding of issues regarding compensation. There is a need of clarity at some points which should be discussed with all stakeholders for better understanding of current regulations. In our view, attention must also be given to academic investigators, during discussion to promote availability of cost-effective treatment in India.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom